HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antozzi, C. Articles by DiDonato, S. Search for Related Content PubMed PubMed Citation Articles by Antozzi, C. Articles by DiDonato, S.

Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme A dehydrogenase and respiratory chain deficiency

Neuromuscular Research Center (Drs. Antozzi, Mora, and Morandi) and the Department of Biochemistry and Genetics (Drs. DiDonato, Garavaglia, and Rimoldi), Istituto Nazionale Neurologico "C. Besta," Milan, and Ospedale di Alessandria (Dr. Ursino), Alessandria, Italy.

We studied the effect of riboflavin treatment on the clinical status and on the activities of ß-oxidation and respiratory chain enzymes in a 69-year-old patient with late-onset myopathy. Before treatment, she was very weak and wasted in the limbs and trunk muscles; also, she could not walk or attend to daily activities. Marked lipid storage was present in the muscle biopsy. The activities of short-chain acyl coenzyme A (acyl-CoA) dehydrogenase (SCAD), medium-chain acyl-CoA dehydrogenase (MCAD), and long-chain acyl-CoA dehydrogenase (LCAD) in isolated muscle mitochondria were reduced to less than 10% of control values. This defect in fatty acid oxidation was associated with a marked deficiency of two flavin-dependent respiratory chain complexes: complex I activity was 20% and complex II activity was 25% of control values. By contrast, the activities of the nonflavin-dependent complex III and complex IV were normal. Western blot analysis of the patient's muscle mitochondrial extracts with antibodies raised against purified SCAD, MCAD, and the -and ß-subunits of the electron transfer flavoprotein (ETF) showed absence of SCAD cross-reacting material (CRM), markedly decreased MCAD-CRM, and normal amounts of both - and ß-ETF-CRM. After riboflavin treatment, the patient's clinical status dramatically improved and morphologic changes in muscle disappeared. SCAD activity increased to 55% of control values, whereas MCAD, LCAD, and complex I and complex II activities normalized. SCAD and MCAD immunoreactivity was restored to normal. On the basis of our experience and the data in the literature, we concluded that some lipid storage myopathies can show dramatic response to riboflavin.

Address correspondence and reprint requests to Dr. Stefano DiDonato, Department of Biochemistry and Genetics, Istituto Nazionale Neurologico "C. Besta," Via Celoria 11, 20133 Milan, Italy.

Received January 28, 1994. Accepted in final form May 4, 1994.

This article has been cited by other articles:

				R. K. J. Olsen, S. E. Olpin, B. S. Andresen, Z. H. Miedzybrodzka, M. Pourfarzam, B. Merinero, F. E. Frerman, M. W. Beresford, J. C. S. Dean, N. Cornelius, et al. ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency Brain, August 1, 2007; 130(8): 2045 - 2054. [Abstract] [Full Text] [PDF]

				S. Koppel, J. Gottschalk, G. F. Hoffmann, H. R. Waterham, H. Blobel, and S. Kolker Late-onset multiple acyl-CoA dehydrogenase deficiency: A frequently missed diagnosis? Neurology, October 24, 2006; 67(8): 1519 - 1519. [Full Text] [PDF]

				A. P. Russell, P. Schrauwen, E. Somm, G. Gastaldi, M. K. C. Hesselink, G. Schaart, E. Kornips, S. K. Lo, D. Bufano, J.-P. Giacobino, et al. Decreased Fatty Acid {beta}-Oxidation in Riboflavin-Responsive, Multiple Acylcoenzyme A Dehydrogenase-Deficient Patients Is Associated with an Increase in Uncoupling Protein-3 J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5921 - 5926. [Abstract] [Full Text] [PDF]

				M. C. Orngreen, D. B. Olsen, and J. Vissing Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose Neurology, October 8, 2002; 59(7): 1046 - 1051. [Abstract] [Full Text] [PDF]

				T. Akompong, S. Eksi, K. Williamson, and K. Haldar Gametocytocidal Activity and Synergistic Interactions of Riboflavin with Standard Antimalarial Drugs against Growth of Plasmodium falciparum In Vitro Antimicrob. Agents Chemother., November 1, 2000; 44(11): 3107 - 3111. [Abstract] [Full Text]

				L. Vergani, M. Barile, C. Angelini, A. B. Burlina, L. Nijtmans, M. P. Freda, C. Brizio, E. Zerbetto, and F. Dabbeni-Sala Riboflavin therapy: Biochemical heterogeneity in two adult lipid storage myopathies Brain, December 1, 1999; 122(12): 2401 - 2411. [Abstract] [Full Text] [PDF]

				I. Tein, R. H. A. Haslam, W. J. Rhead, M. J. Bennett, L. E. Becker, and J. Vockley Short-chain acyl-CoA dehydrogenase deficiency: A cause of ophthalmoplegia and multicore myopathy Neurology, January 1, 1999; 52(2): 366 - 366. [Abstract] [Full Text]

				C. Antozzi and M. Zeviani Cardiomyopathies in disorders of oxidative metabolism Cardiovasc Res, August 1, 1997; 35(2): 184 - 199. [Abstract] [Full Text] [PDF]